Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 195 articles: HTML format Text format

Single Articles

June 2018
1. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
   Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
   J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
   PubMed     Text format     Abstract available
   
   
   
2. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
   Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
   J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909.
   PubMed     Text format     Abstract available
   
   
   May 2018
3. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
   Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
   J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
   PubMed     Text format     Abstract available
   
   
   
4. FASCHING PA, Loibl S, Hu C, Hart SN, et al
   BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
   J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285.
   PubMed     Text format     Abstract available
   
   
   
5. TAYLOR C, McGale P, Bronnum D, Correa C, et al
   Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.
   J Clin Oncol. 2018 May 23:JCO2017776351. doi: 10.1200/JCO.2017.77.6351.
   PubMed     Text format     Abstract available
   
   
   
6. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Liu Y, et al
   Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
   J Clin Oncol. 2018 May 23:JCO2018779736. doi: 10.1200/JCO.2018.77.9736.
   PubMed     Text format     Abstract available
   
   
   
7. DENDULURI N, Chavez-MacGregor M, Telli ML, Eisen A, et al
   Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
   J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.
   PubMed     Text format     Abstract available
   
   
   
8. WANG L, Hong BY, Kennedy SA, Chang Y, et al
   Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
   J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
   PubMed     Text format     Abstract available
   
   
   
9. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
   Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
   J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
   PubMed     Text format     Abstract available
   
   
   April 2018
10. SHERMAN KA, Przezdziecki A, Alcorso J, Kilby CJ, et al
    Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial.
    J Clin Oncol. 2018 Apr 24:JCO2017763318. doi: 10.1200/JCO.2017.76.3318.
    PubMed     Text format     Abstract available
    
    
    
11. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
    Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
    J Clin Oncol. 2018 Apr 24:JCO2017763524. doi: 10.1200/JCO.2017.76.3524.
    PubMed     Text format     Abstract available
    
    
    
12. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
    Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
    J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
    PubMed     Text format     Abstract available
    
    
    
13. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
    Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
    PubMed     Text format     Abstract available
    
    
    
14. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
    Financial Impact of Breast Cancer in Black Versus White Women.
    J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
    PubMed     Text format     Abstract available
    
    
    
15. KORNBLUM N, Zhao F, Manola J, Klein P, et al
    Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
    J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
    PubMed     Text format     Abstract available
    
    
    
16. WANG SY, Dang W, Richman I, Mougalian SS, et al
    Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
    J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
    PubMed     Text format     Abstract available
    
    
    
17. REINER AS, Sisti J, John EM, Lynch CF, et al
    Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    J Clin Oncol. 2018 Apr 5:JCO2017773424. doi: 10.1200/JCO.2017.77.3424.
    PubMed     Text format     Abstract available
    
    
    March 2018
18. HERSHMAN DL, Till C, Shen S, Wright JD, et al
    Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
    J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
    PubMed     Text format     Abstract available
    
    
    
19. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
    Molecular Characterization and Mortality From Breast Cancer in Men.
    J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
    PubMed     Text format     Abstract available
    
    
    
20. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
    Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
    J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
    PubMed     Text format     Abstract available
    
    
    
21. UNTCH M, von Minckwitz G, Gerber B, Schem C, et al
    Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175.
    PubMed     Text format     Abstract available
    
    
    
22. KATZ SJ, Ward KC, Hamilton AS, Mcleod MC, et al
    Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    J Clin Oncol. 2018 Mar 12:JCO2017762369. doi: 10.1200/JCO.2017.76.2369.
    PubMed     Text format     Abstract available
    
    
    
23. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
    US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
    J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
    PubMed     Text format     Abstract available
    
    
    February 2018
24. WHARAM JF, Zhang F, Lu CY, Wagner AK, et al
    Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
    J Clin Oncol. 2018 Feb 28:JCO2017752501. doi: 10.1200/JCO.2017.75.2501.
    PubMed     Text format     Abstract available
    
    
    
25. ZARDAVAS D, Te Marvelde L, Milne RL, Fumagalli D, et al
    Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
    J Clin Oncol. 2018 Feb 22:JCO2017748301. doi: 10.1200/JCO.2017.74.8301.
    PubMed     Text format     Abstract available
    
    
    
26. WAPNIR IL, Price KN, Anderson SJ, Robidoux A, et al
    Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
    J Clin Oncol. 2018 Feb 14:JCO2017765719. doi: 10.1200/JCO.2017.76.5719.
    PubMed     Text format     Abstract available
    
    
    
27. KENNEDY L, Bhatta S, Hechmati G, Buchanan J, et al
    Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
    J Clin Oncol. 2018 Feb 1:JCO2017770115. doi: 10.1200/JCO.2017.77.0115.
    PubMed     Text format    
    
    
    January 2018
28. NEUMAN HB, Schumacher JR, Francescatti AB, Adesoye T, et al
    Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
    J Clin Oncol. 2018 Jan 31:JCO2017755389. doi: 10.1200/JCO.2017.75.5389.
    PubMed     Text format     Abstract available
    
    
    
29. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
    J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
    PubMed     Text format     Abstract available
    
    
    
30. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
    Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
    PubMed     Text format     Abstract available
    
    
    
31. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
    PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
    PubMed     Text format     Abstract available
    
    
    
32. HAWLEY ST, Li Y, An LC, Resnicow K, et al
    Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
    J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
    PubMed     Text format     Abstract available
    
    
    
33. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
    PubMed     Text format     Abstract available
    
    
    
34. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
    Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
    PubMed     Text format     Abstract available
    
    
    
35. ZIVANOVIC BUJAK A, Dawson SJ
    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017765461. doi: 10.1200/JCO.2017.76.5461.
    PubMed     Text format    
    
    
    
36. STOVER DG, Parsons HA, Ha G, Freeman SS, et al
    Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.
    PubMed     Text format     Abstract available
    
    
    December 2017
37. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Text format     Abstract available
    
    
    
38. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2017 Dec 15:JCO2017747824. doi: 10.1200/JCO.2017.74.7824.
    PubMed     Text format     Abstract available
    
    
    
39. BLUM JL, Robert N, Andersen J, Favret A, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2017 Dec 11:JCO2017753756. doi: 10.1200/JCO.2017.75.3756.
    PubMed     Text format    
    
    
    November 2017
40. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
    Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
    J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
    PubMed     Text format     Abstract available
    
    
    
41. HWONG AR, Mangurian C
    Improving Breast Cancer Screening and Care for Women With Severe Mental Illness.
    J Clin Oncol. 2017 Nov 2:JCO2017760462. doi: 10.1200/JCO.2017.76.0462.
    PubMed     Text format    
    
    
    October 2017
42. GANZ PA, Romond EH, Cecchini RS, Rastogi P, et al
    Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pacl
    J Clin Oncol. 2017 Oct 26:JCO2017741165. doi: 10.1200/JCO.2017.74.1165.
    PubMed     Text format     Abstract available
    
    
    
43. JEMAL A, Robbins AS, Lin CC, Flanders WD, et al
    Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
    J Clin Oncol. 2017 Oct 16:JCO2017737932. doi: 10.1200/JCO.2017.73.7932.
    PubMed     Text format     Abstract available
    
    
    
44. VAN POZNAK C, Somerfield MR, Barlow WE, Biermann JS, et al
    Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
    J Clin Oncol. 2017 Oct 16:JCO2017754614. doi: 10.1200/JCO.2017.75.4614.
    PubMed     Text format     Abstract available
    
    
    
45. SHAPIRO CL, Moriarty JP, Dusetzina S, Himelstein AL, et al
    Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    J Clin Oncol. 2017 Oct 12:JCO2017737437. doi: 10.1200/JCO.2017.73.7437.
    PubMed     Text format     Abstract available
    
    
    
46. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
    Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
    J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
    PubMed     Text format     Abstract available
    
    
    
47. GOETZ MP, Toi M, Campone M, Sohn J, et al
    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
    PubMed     Text format     Abstract available
    
    
    September 2017
48. WU JW, Azoulay L, Majdan A, Boivin JF, et al
    Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    J Clin Oncol. 2017 Sep 27:JCO2017734491. doi: 10.1200/JCO.2017.73.4491.
    PubMed     Text format     Abstract available
    
    
    
49. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
    Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
    J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
    PubMed     Text format     Abstract available
    
    
    August 2017
50. GOETZ MP, Suman VJ, Reid JM, Northfelt DW, et al
    First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
    J Clin Oncol. 2017 Aug 30:JCO2017733246. doi: 10.1200/JCO.2017.73.3246.
    PubMed     Text format     Abstract available
    
    
    
51. KUIJER A, Straver M, den Dekker B, van Bommel ACM, et al
    Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
    J Clin Oncol. 2017;35:2814-2819.
    PubMed     Text format     Abstract available
    
    
    
52. CHIEN AJ, Rugo HS
    Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?
    J Clin Oncol. 2017 Aug 7:JCO2017735670. doi: 10.1200/JCO.2017.73.5670.
    PubMed     Text format    
    
    
    July 2017
53. SJOSTROM M, Lundstedt D, Hartman L, Holmberg E, et al
    Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.
    J Clin Oncol. 2017 Jul 31:JCO2017727263. doi: 10.1200/JCO.2017.72.7263.
    PubMed     Text format     Abstract available
    
    
    
54. FREEDMAN RA, Keating NL, Pace LE, Lii J, et al
    Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.
    J Clin Oncol. 2017 Jul 27:JCO2016721209. doi: 10.1200/JCO.2016.72.1209.
    PubMed     Text format     Abstract available
    
    
    
55. REEDER-HAYES KE, Meyer AM, Hinton SP, Meng K, et al
    Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Jul 20:JCO2016714345. doi: 10.1200/JCO.2016.71.4345.
    PubMed     Text format     Abstract available
    
    
    
56. FOURNIER A, Mesrine S, Gelot A, Fagherazzi G, et al
    Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women.
    J Clin Oncol. 2017 Jul 14:JCO2016714337. doi: 10.1200/JCO.2016.71.4337.
    PubMed     Text format     Abstract available
    
    
    
57. WALLNER LP, Li Y, Furgal AKC, Friese CR, et al
    Patient Preferences for Primary Care Provider Roles in Breast Cancer Survivorship Care.
    J Clin Oncol. 2017 Jul 12:JCO2017731307. doi: 10.1200/JCO.2017.73.1307.
    PubMed     Text format     Abstract available
    
    
    
58. KROP I, Ismaila N, Andre F, Bast RC, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2017 Jul 10:JCO2017740472. doi: 10.1200/JCO.2017.74.0472.
    PubMed     Text format     Abstract available
    
    
    
59. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Text format     Abstract available
    
    
    
60. ENRIGHT KA, Taback N, Powis ML, Gonzalez A, et al
    Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data.
    J Clin Oncol. 2017 Jul 6:JCO2016707950. doi: 10.1200/JCO.2016.70.7950.
    PubMed     Text format     Abstract available
    
    
    
61. HARBECK N, Gluz O, Christgen M, Kates RE, et al
    De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and The
    J Clin Oncol. 2017 Jul 6:JCO2016719815. doi: 10.1200/JCO.2016.71.9815.
    PubMed     Text format     Abstract available
    
    
    June 2017
62. CURIGLIANO G, Criscitiello C
    Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
    J Clin Oncol. 2017 Jun 29:JCO2017725960. doi: 10.1200/JCO.2017.72.5960.
    PubMed     Text format     Abstract available
    
    
    
63. EJLERTSEN B, Tuxen MK, Jakobsen EH, Jensen MB, et al
    Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
    J Clin Oncol. 2017 Jun 29:JCO2017723494. doi: 10.1200/JCO.2017.72.3494.
    PubMed     Text format     Abstract available
    
    
    
64. SMITH SG, Sestak I, Howell A, Forbes J, et al
    Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
    J Clin Oncol. 2017 Jun 29:JCO2016717439. doi: 10.1200/JCO.2016.71.7439.
    PubMed     Text format     Abstract available
    
    
    
65. SAHA P, Regan MM, Pagani O, Francis PA, et al
    Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    J Clin Oncol. 2017 Jun 27:JCO2016720946. doi: 10.1200/JCO.2016.72.0946.
    PubMed     Text format     Abstract available
    
    
    
66. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Thomson CA, et al
    Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial.
    J Clin Oncol. 2017 Jun 27:JCO2016720326. doi: 10.1200/JCO.2016.72.0326.
    PubMed     Text format     Abstract available
    
    
    
67. POWLES TJ, Paterson AHG, Gralow JR
    Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.
    J Clin Oncol. 2017 Jun 27:JCO2017736157. doi: 10.1200/JCO.2017.73.6157.
    PubMed     Text format    
    
    
    
68. DHESY-THIND S, Fletcher GG, Blanchette PS, Clemons MJ, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2017;35:2062-2081.
    PubMed     Text format     Abstract available
    
    
    
69. STOLLEY M, Sheean P, Gerber B, Arroyo C, et al
    Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors.
    J Clin Oncol. 2017 Jun 19:JCO2016719856. doi: 10.1200/JCO.2016.71.9856.
    PubMed     Text format     Abstract available
    
    
    
70. GONCALVES R, Reinert T, Ellis MJ
    Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 5:JCO2017730424. doi: 10.1200/JCO.2017.73.0424.
    PubMed     Text format    
    
    
    
71. GRIGGS JJ, Wolff AC
    Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
    J Clin Oncol. 2017 Jun 3:JCO2017739375. doi: 10.1200/JCO.2017.73.9375.
    PubMed     Text format    
    
    
    
72. SLEDGE GW JR, Toi M, Neven P, Sohn J, et al
    MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    J Clin Oncol. 2017 Jun 3:JCO2017737585. doi: 10.1200/JCO.2017.73.7585.
    PubMed     Text format     Abstract available
    
    
    
73. WANDER SA, Mayer EL, Burstein HJ
    Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 3:JCO2017739482. doi: 10.1200/JCO.2017.73.9482.
    PubMed     Text format     Abstract available
    
    
    
74. BEALE DJ
    Conclusion Based on Insufficient Data in Study of Protein Intake Association With Breast Cancer Survival.
    J Clin Oncol. 2017;35:1857.
    PubMed     Text format    
    
    
    May 2017
75. VENTZ S, Alexander BM, Parmigiani G, Gelber RD, et al
    Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 22:JCO2016701169. doi: 10.1200/JCO.2016.70.1169.
    PubMed     Text format     Abstract available
    
    
    
76. MERETOJA TJ, Andersen KG, Bruce J, Haasio L, et al
    Clinical Prediction Model and Tool for Assessing Risk of Persistent Pain After Breast Cancer Surgery.
    J Clin Oncol. 2017;35:1660-1667.
    PubMed     Text format     Abstract available
    
    
    
77. MA F, Li Q, Chen S, Zhu W, et al
    Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 12:JCO2016696179. doi: 10.1200/JCO.2016.69.6179.
    PubMed     Text format     Abstract available
    
    
    
78. IRWIN MR, Olmstead R, Carrillo C, Sadeghi N, et al
    Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial.
    J Clin Oncol. 2017 May 10:JCO2016710285. doi: 10.1200/JCO.2016.71.0285.
    PubMed     Text format     Abstract available
    
    
    
79. KVILLEMO P, Mittendorfer-Rutz E, Branstrom R, Nilsson K, et al
    Sickness Absence and Disability Pension After Breast Cancer Diagnosis: A 5-Year Nationwide Cohort Study.
    J Clin Oncol. 2017 May 1:JCO2015660613. doi: 10.1200/JCO.2015.66.0613.
    PubMed     Text format     Abstract available
    
    
    April 2017
80. HANNA WM, Slodkowska E, Lu FI, Nafisi H, et al
    Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    J Clin Oncol. 2017 Apr 26:JCO2016705319. doi: 10.1200/JCO.2016.70.5319.
    PubMed     Text format     Abstract available
    
    
    
81. URRUTICOECHEA A, Rizwanullah M, Im SA, Ruiz ACS, et al
    Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Th
    J Clin Oncol. 2017 Apr 24:JCO2016706267. doi: 10.1200/JCO.2016.70.6267.
    PubMed     Text format     Abstract available
    
    
    
82. MALY RC, Liang LJ, Liu Y, Griggs JJ, et al
    Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors.
    J Clin Oncol. 2017 Apr 18:JCO2016689497. doi: 10.1200/JCO.2016.68.9497.
    PubMed     Text format     Abstract available
    
    
    
83. AHN S, Port ER
    Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement.
    J Clin Oncol. 2017 Apr 14:JCO2017728816. doi: 10.1200/JCO.2017.72.8816.
    PubMed     Text format    
    
    
    
84. KURIAN AW, Li Y, Hamilton AS, Ward KC, et al
    Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Apr 12:JCO2016716480. doi: 10.1200/JCO.2016.71.6480.
    PubMed     Text format     Abstract available
    
    
    
85. BLUM JL, Flynn PJ, Yothers G, Asmar L, et al
    Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    J Clin Oncol. 2017 Apr 11:JCO2016714147. doi: 10.1200/JCO.2016.71.4147.
    PubMed     Text format     Abstract available
    
    
    
86. BORGQUIST S, Giobbie-Hurder A, Ahern TP, Garber JE, et al
    Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
    J Clin Oncol. 2017;35:1179-1188.
    PubMed     Text format     Abstract available
    
    
    March 2017
87. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Text format     Abstract available
    
    
    
88. BARDIA A, Mayer IA, Diamond JR, Moroose RL, et al
    Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2017 Mar 14:JCO2016708297. doi: 10.1200/JCO.2016.70.8297.
    PubMed     Text format     Abstract available
    
    
    
89. SONNENBLICK A, Agbor-Tarh D, Bradbury I, Di Cosimo S, et al
    Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016697722. doi: 10.1200/JCO.2016.69.7722.
    PubMed     Text format     Abstract available
    
    
    February 2017
90. HUMMEL SB, van Lankveld JJ, Oldenburg HS, Hahn DE, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2017 Feb 27:JCO2016696021. doi: 10.1200/JCO.2016.69.6021.
    PubMed     Text format     Abstract available
    
    
    
91. LYMAN GH, Somerfield MR, Bosserman LD, Perkins CL, et al
    Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017;35:561-564.
    PubMed     Text format     Abstract available
    
    
    January 2017
92. SYMMANS WF, Wei C, Gould R, Yu X, et al
    Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    J Clin Oncol. 2017 Jan 30:JCO2015631010. doi: 10.1200/JCO.2015.63.1010.
    PubMed     Text format     Abstract available
    
    
    
93. LOIBL S, Denkert C
    How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    J Clin Oncol. 2017 Jan 30:JCO2016713503. doi: 10.1200/JCO.2016.71.3503.
    PubMed     Text format    
    
    
    
94. SMITH I, Yardley D, Burris H, De Boer R, et al
    Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluat
    J Clin Oncol. 2017 Jan 23:JCO2016692871. doi: 10.1200/JCO.2016.69.2871.
    PubMed     Text format     Abstract available
    
    
    
95. CHERAGHI Z, Ayubi E, Doosti-Irani A
    Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016710715. doi: 10.1200/JCO.2016.71.0715.
    PubMed     Text format    
    
    
    
96. HOLMES MD, Wang J, Hankinson SE, Tamimi RM, et al
    Protein Intake and Breast Cancer Survival in the Nurses' Health Study.
    J Clin Oncol. 2017;35:325-333.
    PubMed     Text format     Abstract available
    
    
    
97. SUPPLI NP, Johansen C, Kessing LV, Toender A, et al
    Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study.
    J Clin Oncol. 2017;35:334-342.
    PubMed     Text format     Abstract available
    
    
    
98. VAN DEN BOGAARD VA, Ta BD, van der Schaaf A, Bouma AB, et al
    Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.
    J Clin Oncol. 2017 Jan 17:JCO2016698480. doi: 10.1200/JCO.2016.69.8480.
    PubMed     Text format     Abstract available
    
    
    
99. RECHT A
    Radiation-Induced Heart Disease After Breast Cancer Treatment: How Big a Problem, and How Much Can-and Should-We Try to Reduce It?
    J Clin Oncol. 2017 Jan 17:JCO2016714113. doi: 10.1200/JCO.2016.71.4113.
    PubMed     Text format    
    
    
    
100. DEL MASTRO L
     Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer.
     J Clin Oncol. 2017 Jan 17:JCO2016682393. doi: 10.1200/JCO.2016.68.2393.
     PubMed     Text format    
     
     
     
101. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
     Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
     J Clin Oncol. 2017;35:141-148.
     PubMed     Text format     Abstract available
     
     
     
102. MEGGETTO O, Maunsell E, Chlebowski R, Goss P, et al
     Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
     J Clin Oncol. 2017 Jan 9:JCO2016688895.
     PubMed     Text format     Abstract available
     
     
     
103. ELLIS MJ, Suman VJ, Hoog J, Goncalves R, et al
     Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
     J Clin Oncol. 2017 Jan 3:JCO2016694406.
     PubMed     Text format     Abstract available
     
     
     
104. FARIAS AJ, Du XL
     Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
     J Clin Oncol. 2017;35:86-95.
     PubMed     Text format     Abstract available
     
     
     December 2016
105. CUZICK J, Brentnall AR, Segal C, Byers H, et al
     Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
     J Clin Oncol. 2016 Dec 28:JCO2016698944.
     PubMed     Text format     Abstract available
     
     
     
106. CHLEBOWSKI RT
     Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention.
     J Clin Oncol. 2016 Dec 28:JCO2016709386.
     PubMed     Text format    
     
     
     
107. JANELSINS MC, Heckler CE, Peppone LJ, Kamen C, et al
     Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
     J Clin Oncol. 2016 Dec 28:JCO2016685856.
     PubMed     Text format     Abstract available
     
     
     
108. KIM HS, Umbricht CB, Illei PB, Cimino-Mathews A, et al
     Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
     J Clin Oncol. 2016;34:4390-4397.
     PubMed     Text format     Abstract available
     
     
     
109. FREEDMAN RA, Foster JC, Seisler DK, Lafky JM, et al
     Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
     J Clin Oncol. 2016 Dec 19:JCO2016694182.
     PubMed     Text format     Abstract available
     
     
     
110. JIRALERSPONG S, Goodwin PJ
     Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.
     J Clin Oncol. 2016;34:4203-4216.
     PubMed     Text format     Abstract available
     
     
     November 2016
111. ALFANO CM, Peng J, Andridge RR, Lindgren ME, et al
     Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
     J Clin Oncol. 2016 Nov 28:JCO2016671883.
     PubMed     Text format     Abstract available
     
     
     
112. VISVANATHAN K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, et al
     Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
     J Clin Oncol. 2016 Nov 21:JCO2015662080.
     PubMed     Text format     Abstract available
     
     
     
113. WALLNER LP, Abrahamse P, Uppal JK, Friese CR, et al
     Involvement of Primary Care Physicians in the Decision Making and Care of Patients With Breast Cancer.
     J Clin Oncol. 2016;34:3969-3975.
     PubMed     Text format     Abstract available
     
     
     
114. JHAVERI K
     MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.
     J Clin Oncol. 2016 Nov 14:JCO2016702712.
     PubMed     Text format    
     
     
     October 2016
115. ZARDAVAS D, Suter TM, Van Veldhuisen DJ, Steinseifer J, et al
     Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stud
     J Clin Oncol. 2016 Oct 23:JCO2015657916. doi: 10.1200/JCO.2015.65.7916.
     PubMed     Text format     Abstract available
     
     
     August 2016
116. PRESS MF, Sauter G, Buyse M, Fourmanoir H, et al
     HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
     J Clin Oncol. 2016 Aug 29. pii: JCO666693.
     PubMed     Text format     Abstract available
     
     
     
117. COPUR MS, Ramaekers R, Gauchan D, Norvell M, et al
     Recent ASCO Guideline on the Use of Biomarkers for Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
     J Clin Oncol. 2016 Aug 22. pii: JCO682385.
     PubMed     Text format    
     
     
     
118. SGROI DC, Brufsky A
     Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.
     J Clin Oncol. 2016 Aug 22. pii: JCO672949.
     PubMed     Text format    
     
     
     
119. BRADBURY AR, Patrick-Miller L, Schwartz LA, Egleston BL, et al
     Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History.
     J Clin Oncol. 2016 Aug 22. pii: JCO663450.
     PubMed     Text format     Abstract available
     
     
     
120. MAYER EL, Burstein HJ
     Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
     J Clin Oncol. 2016 Aug 22. pii: JCO684068.
     PubMed     Text format    
     
     
     
121. HASEGAWA T, Uno H, Wei LJ
     How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
     J Clin Oncol. 2016 Aug 9. pii: JCO672055.
     PubMed     Text format    
     
     
     
122. PARTRIDGE AH, Hughes ME, Warner ET, Ottesen RA, et al
     Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
     J Clin Oncol. 2016 Aug 1. pii: JCO658013.
     PubMed     Text format     Abstract available
     
     
     July 2016
123. BAIK SH, Gallo LC, Wells KJ
     Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review.
     J Clin Oncol. 2016 Jul 25. pii: JCO675454.
     PubMed     Text format     Abstract available
     
     
     
124. GUENANCIA C, Lefebvre A, Cardinale D, Yu AF, et al
     Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2016 Jul 25. pii: JCO674846.
     PubMed     Text format     Abstract available
     
     
     
125. STRULOV SHACHAR S, Hurria A, Muss HB
     Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
     J Clin Oncol. 2016 Jul 18. pii: JCO688242.
     PubMed     Text format    
     
     
     
126. LAURING J, Wolff AC
     Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.
     J Clin Oncol. 2016 Jul 5. pii: JCO684720.
     PubMed     Text format    
     
     
     June 2016
127. COLLEONI M, Gray KP, Gelber S, Lang I, et al
     Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
     J Clin Oncol. 2016 Jun 20. pii: JCO656595.
     PubMed     Text format     Abstract available
     
     
     
128. JOHANNSEN M, O'Connor M, O'Toole MS, Jensen AB, et al
     Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial.
     J Clin Oncol. 2016 Jun 20. pii: JCO650770.
     PubMed     Text format     Abstract available
     
     
     
129. SCHMIDT MK, Hogervorst F, van Hien R, Cornelissen S, et al
     Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
     J Clin Oncol. 2016 Jun 6. pii: JCO665844.
     PubMed     Text format     Abstract available
     
     
     
130. FRIBBENS C, O'Leary B, Kilburn L, Hrebien S, et al
     Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
     J Clin Oncol. 2016 Jun 6. pii: JCO673061.
     PubMed     Text format     Abstract available
     
     
     May 2016
131. LENGACHER CA, Reich RR, Paterson CL, Ramesar S, et al
     Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.
     J Clin Oncol. 2016 May 31. pii: JCO657874.
     PubMed     Text format     Abstract available
     
     
     
132. LIVI L, Meattini I, Kaidar-Person O, Poortmans PM, et al
     Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology.
     J Clin Oncol. 2016 May 23. pii: JCO664276.
     PubMed     Text format    
     
     
     
133. HINDIE E, Groheux D
     Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection.
     J Clin Oncol. 2016 May 23. pii: JCO674531.
     PubMed     Text format    
     
     
     
134. RUGO HS, Rumble RB, Macrae E, Barton DL, et al
     Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
     J Clin Oncol. 2016 May 23. pii: JCO671487.
     PubMed     Text format     Abstract available
     
     
     
135. KUERER HM
     Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer.
     J Clin Oncol. 2016 May 23. pii: JCO668046.
     PubMed     Text format    
     
     
     
136. JONES LW, Habel LA, Weltzien E, Castillo A, et al
     Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.
     J Clin Oncol. 2016 May 23. pii: JCO656603.
     PubMed     Text format     Abstract available
     
     
     
137. WOLMARK N, Mamounas EP, Baehner FL, Butler SM, et al
     Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/
     J Clin Oncol. 2016 May 23. pii: JCO626630.
     PubMed     Text format     Abstract available
     
     
     
138. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
     Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.
     J Clin Oncol. 2016 May 9. pii: JCO656272.
     PubMed     Text format     Abstract available
     
     
     
139. MCCARTHY AM, Bristol M, Domchek SM, Groeneveld PW, et al
     Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
     J Clin Oncol. 2016 May 9. pii: JCO660019.
     PubMed     Text format     Abstract available
     
     
     
140. ACCORDINO MK, Wright JD, Vasan S, Neugut AI, et al
     Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
     J Clin Oncol. 2016 May 9. pii: JCO666313.
     PubMed     Text format     Abstract available
     
     
     
141. CHECK DK, Samuel CA, Rosenstein DL, Dusetzina SB, et al
     Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer.
     J Clin Oncol. 2016 May 9. pii: JCO648162.
     PubMed     Text format     Abstract available
     
     
     
142. AXILBUND JE
     Panel Testing Is Not a Panacea.
     J Clin Oncol. 2016;34:1433-5.
     PubMed     Text format    
     
     
     April 2016
143. RAYSON D
     White Knuckling.
     J Clin Oncol. 2016;34:1419-20.
     PubMed     Text format    
     
     
     
144. HART V, Sprague BL, Lakoski SG, Hampton JM, et al
     Trends in Health-Related Quality of Life After a Diagnosis of Ductal Carcinoma In Situ.
     J Clin Oncol. 2016;34:1323-9.
     PubMed     Text format     Abstract available
     
     
     
145. CARMONA R, Zakeri K, Green G, Hwang L, et al
     Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
     J Clin Oncol. 2016;34:1270-7.
     PubMed     Text format     Abstract available
     
     
     
146. SMITH GL
     Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In Situ in the United States.
     J Clin Oncol. 2016;34:1172-4.
     PubMed     Text format    
     
     
     March 2016
147. PARK JH, Anderson WF, Gail MH
     Reply to L.A. Newman.
     J Clin Oncol. 2016;34:1014-5.
     PubMed     Text format    
     
     
     
148. ELKIN EB, Hudis CA
     Reply to L.A. Newman.
     J Clin Oncol. 2016;34:1015.
     PubMed     Text format    
     
     
     
149. AHN S, Port ER
     Lymphedema Precautions: Time to Abandon Old Practices?
     J Clin Oncol. 2016;34:655-8.
     PubMed     Text format     Abstract available
     
     
     February 2016
150. RUDDY KJ, Risendal BC, Garber JE, Partridge AH, et al
     Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
     J Clin Oncol. 2016;34:539-41.
     PubMed     Text format    
     
     
     January 2016
151. YOO W, Ansa BE, Coughlin SS, Whitehead MS, et al
     Determinants of adherence to physical activity guidelines among overweight and obese African American breast cancer survivors: Implications for intervention approach.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
152. CLEMONS MJ, Mazzarello S, Vandermeer L, Jones L, et al
     Weight control strategies in breast cancer patients: A systematic review.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
153. HARRIGAN M, Cartmel B, Playdon M, Zhou Y, et al
     Effect of weight history on ability to lose weight after a 6-month randomized controlled weight loss trial in overweight breast cancer survivors: The Lifestyle, Exercise and Nutrition (LEAN) study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
154. BARRY WT, Ruddy KJ, Greaney M, Rosenberg SM, et al
     Impact of Young and Strong on physical activity in young breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
155. HADDAD N, Schnyer R, Neri E, Packer MM, et al
     Moderators of acupuncture effectiveness in breast cancer survivors: Randomized clinical trial (RCT).
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
156. CHAMPION V
     Examining the relationship between social cognitive processing and depressive symptoms in long-term breast cancer survivors and their partners.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
157. LEE S, Bae SY, Lee JE, Kim SW, et al
     Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
158. SILVA HC, Mapp G, Terrell D
     Implementation of distress screening for breast cancer patients.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
159. BERYL L, Gillespie K, Rendle K, May SG, et al
     "Hot Girls Pearls" and other coping strategies for women experiencing adverse effects from endocrine therapy in the treatment of breast cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
160. COHEE AA, Monahan P, Stump TE, Miller K, et al
     Quality of life difficulties in partners of young breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
161. ANSA BE, Yoo W, Whitehead MS, Coughlin SS, et al
     Breast cancer recurrence risk-reduction beliefs and behaviors among African American breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
162. ROCK CL, Sedjo RL, Toriola A, Liu J, et al
     Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
163. LIN JJ, Franco R, Egorova N
     Breast cancer: Does where you get treated affect survival?
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
164. YEAHIA R, Korenstein D
     The evidence base in support of breast cancer surveillance guidelines: Flying without a net?
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
165. LEE J, Kim Z, Lee MH, Lee I, et al
     Development of second primary cancers in breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
166. GONZALES FA, Shariff-Marco S, Dwyer LA, Nuru-Jeter A, et al
     Discrimination and quality of life among breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
167. BALLARD A
     Exploring factors influencing sexual satisfaction among breast cancer survivors: The role of sexual communication.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
168. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
     Association of anxiety and depressive symptoms with differing needs among recent breast cancer (BC) survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
169. CHEN SP, Horng CF, Hsieh LL, Hsu KH, et al
     A randomized controlled study for the long term follow-up of breast cancer survivors: A primary care physician (PCP) coordinated care delivery model.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
170. PACKER MM, George H, Koopman C, Innominato PF, et al
     Associations between morning-evening chronotype, fatigue, and QOL in breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
171. MUSTAFA ALI MK, Moeller M, Rybicki LA
     Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
172. DE RIDDER M, Lamote J, Fontaine C, Van Parijs H, et al
     Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
173. PAUL E, Yang GJ, Phillips S, Bowles J, et al
     A new paradigm for patient-centered breast cancer care.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
174. VICINI FA
     The increasing role of breast cancer lymphedema screening, diagnosis, and management as part of evidence-based breast cancer survivorship.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
175. MERRIMAN J, Gentry A, Ahrendt GM, Brufsky A, et al
     Predictors of trajectories of cognitive change in women with breast cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
176. SATPUTE SR
     Systematic development of a a breast cancer survivorship program at a small independent oncology practice.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
177. SINHA AK, Hsu L, Patangan M, Le-Petross HT, et al
     Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
178. FONTAINE C, Vanhoeij M, Lamote J, De Greve J, et al
     The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
179. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
     Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
180. ESSER M, Singh N, Rowe J, McCann M, et al
     Measuring knowledge gained for young breast cancer survivors and co-survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
181. GUGLIELMINO J, Labban JD, Rugo HS, Anders CK, et al
     Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
182. KHOSLA P, Molnar J, Corona ME, Garcia SM, et al
     Improving patient participation in a breast cancer survivorship program at a safety net hospital.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
183. CORRELL JA, Peterson LL
     Psychosocial well-being assessment in women with breast cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
184. GROEN WG, Oldenburg HS, Wouters MW, Aaronson NK, et al
     Evaluation of an interactive portal for breast cancer survivors: Use, satisfaction, and preliminary effects.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
185. ROSENBERG SM, Gelber SI, Ruddy KJ, Morgan E, et al
     Post-traumatic stress disorder in young breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
186. MCDOWELL K, Brown S, Serrano M, Lai LL, et al
     Evaluating a clinically and culturally informed survivorship care plan trial for African American breast cancer survivors (AABCS).
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
187. YEE S, Glass K, Foong S, Kennedy ED, et al
     Perspective of young breast cancer survivors (BCS) on fertility preservation (FP) referral.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
188. LI D
     Patterns of health care-related multimorbidity among breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
189. TANO J, Conde FA
     Impact of chemotherapy on health-related quality of life among ethnically diverse breast cancer survivors treated with breast-conserving therapy.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
190. HOCKING WG, Wiegmann D, Yen TY, Gribble M, et al
     Evaluation of electronic care plan usage and usefulness among breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
191. TSUCHIYA K, Nishijima C, Suzuki N, Tsugawa K, et al
     Our act on fertility preservation for young breast cancer patients in our single institute.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
192. ABRAHAMSE P, Friese CR, Katz SJ, Hawley ST, et al
     Primary care provider engagement about breast cancer care during treatment: Results from the iCanCare Study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
193. PIACENTINE LB, Robinson KM, Ng AV, Waltke LJ, et al
     Underserved community-based walking program for breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
194. ZHENG L, Graves KD, Hurtado-de-Mendoza A, Tadasse M, et al
     Opportunities for precision medicine: Factors associated with participation in genetic research among breast cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
195. GROOME P, Turner D, Jorgensen M, Kendell C, et al
     Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: